Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TMEM176B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEM176B ECL-Fc Fusion Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. HEK293 Expressed for native glycosylation. |
View TMEM176B Products |
| Gene Delivery | TMEM176B Promise-ORF / Lentivirus Full-length ORF for stable cell line construction (Flow Cytometry/Calcium Flux). |
View TMEM176B Products |
| Benchmark Ab | Anti-TMEM176B Recombinant Antibody Recombinant positive control for assay validation. |
View TMEM176B Products |
| Validator | TMEM176B siRNA Set For target knockdown and specificity verification. |
View TMEM176B Products |
| Related Target A | TMEM176A Highly homologous partner that forms hetero-oligomers with TMEM176B; essential for counter-screening. |
View TMEM176A Products |
| Related Target B | NLRP3 Downstream inflammasome pathway effector regulated by TMEM176B ion-channel activity. |
View NLRP3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass membrane conformation loss | Lentivirus for stable cell line generation to preserve native 4-pass transmembrane structure |
| Subfamily cross-reactivity (TMEM176A) | Homolog panel screening using sequence-verified TMEM176A and TMEM176B targets |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live TMEM176B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TMEM176B therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule inhibitors and targeted biologics. As first-generation therapies reach the clinic, the next wave of R&D is targeting the coordination of TMEM176B inhibition with immune checkpoint blockade to overcome cold tumor microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Solid Tumors, Inflammatory Diseases | Ion channel function assays (Need Lentivirus for stable cell line construction) |
| Monoclonal Antibodies (mAbs) | Biopharma Innovators | Lymphoma, Glioblastoma | Epitope binding and internalization (Need native-conformation HEK293 antigens) |
| Combination Therapies (w/ Anti-PD-1) | Clinical Investigators | Refractory / Cold Tumors | Synergistic pathway validation (Need NLRP3 and TMEM176A control panels) |